🇺🇸 FDA
Patent

US 7759330

21-substituted progesterone derivatives as new antiprogestational agents

granted A61PA61P15/00A61P15/04

Quick answer

US patent 7759330 (21-substituted progesterone derivatives as new antiprogestational agents) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Jul 15 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Jul 20 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 15 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
38
CPC classes
A61P, A61P15/00, A61P15/04, A61P15/08, A61P5/24